头颈部鳞状细胞癌的免疫治疗与衰老细胞清除药物:2期试验结果
研究对51例接受新辅助化疗免疫治疗的头颈鳞癌患者行单细胞RNA及TCR/BCR测序,发现应答不佳与CCR7+CD4+初始T细胞和CD27+记忆B细胞减少及免疫衰老相关基因高表达有关;在自然衰老和Ercc1缺陷小鼠中,衰老细胞清除药物可增强免疫治疗疗效;COIS-01试验中该联合抗PD-1治疗的主要病理缓解率为33.3%(95%CI 16.6-54.7%),3-4级不良事件发生率为4.2%。
要点
- 应答不佳与CCR7+CD4+初始T细胞及CD27+记忆B细胞减少、免疫衰老相关基因高表达相关。
- 自然衰老和Ercc1缺陷小鼠中,衰老细胞清除药物增强免疫治疗疗效。
- COIS-01试验中衰老细胞清除药物联合抗PD-1治疗主要病理缓解率33.3%,3-4级不良事件发生率4.2%。
核心结论
- 免疫衰老特征影响免疫治疗疗效,衰老细胞清除药物联合抗PD-1治疗显示出有前景的疗效和良好的安全性。
研究设计与样本
- 2期临床试验纳入51例接受新辅助化疗免疫治疗的癌症患者,对肿瘤和血液样本行单细胞RNA及TCR和BCR测序。
- 使用自然衰老小鼠和Ercc1缺陷早衰小鼠研究衰老细胞清除药物对免疫治疗疗效的影响。
- 开展2期临床试验COIS-01研究衰老细胞清除药物联合抗PD-1治疗。
主要发现
- 应答不佳与CCR7+CD4+初始T细胞和CD27+记忆B细胞水平降低相关,并与T细胞和B细胞亚群中免疫衰老相关基因表达升高相关。
- 在多种实体瘤中,衰老细胞清除药物通过减轻免疫衰老增强免疫治疗疗效。
- COIS-01试验中联合治疗的主要病理缓解率为33.3%(95%CI 16.6-54.7%),3-4级不良事件发生率为4.2%。
关键数值与推荐
- COIS-01试验主要病理缓解率为33.3%(95%CI 16.6-54.7%)。
- COIS-01试验3-4级不良事件发生率为4.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent advancements in cancer immunotherapy have improved patient outcomes, yet responses to immunotherapy remain moderate. Immunosenescence has been shown to contribute to the development and progression of various diseases; however, its specific role in solid tumors has not been fully delineated. Here we conducted a phase 2 clinical trial involving 51 patients with cancer undergoing neoadjuvant chemoimmunotherapy and applied single-cell RNA as well as TCR and BCR sequencing on tumor and blood samples to elucidate the immune cell perturbations. Our findings associate poor response with reduced levels of CCR7+ CD4+ naive T cells and CD27+ memory B cells, as well as higher expression of immunosenescence-related genes in T and B cell subsets. Using naturally aged mice and Ercc1-deficient mice (premature aging), we found that senolytics enhance the therapeutic efficacy of immunotherapy in multiple solid tumors by mitigating immunosenescence. Notably, we launched a phase 2 clinical trial (COIS-01) investigating the combination of senolytics with anti-PD-1 therapy. The results showed that the combination therapy achieved a 33.3% (95% confidence interval 16.6-54.7%) major pathological response rate with a low incidence of grade 3-4 adverse events (4.2%). These findings underscore the pivotal role of immunosenescence characteristics in influencing the effectiveness of immunotherapy and suggest a promising therapeutic efficacy along with a favorable safety for the combination of senolytics with anti-PD-1 therapy. ClinicalTrials.gov Identifier: OOC-001( NCT04718415 ) and COIS-01( NCT05724329 ).
引用
- Liu N, Wu J, Deng E, et al. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results. Nat Med. 2025. PMID: 40855191. doi:10.1038/s41591-025-03873-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。